Objective: We aimed to identify key principles of targeted therapy of protein kinases and their application to the management of solid tumors. Background: Concurrent advances in tumor genomic analysis and molecular inhibitor development have dramatically impacted the diagnosis and treatment of solid tumors, and common themes regarding the use of kinase inhibitors are developing. Methods: The list of kinase inhibitors that have been approved by the US Food and Drug Administration was reviewed and articles related to the agents were searched in the PubMed database up until December 2015. We included pivotal, randomized controlled phase 2 and 3 trials, and also pertinent preclinical studies. Results: Small molecule inhibitors targeted against driver kinases, overactive in selected subsets of solid tumors, elicit improved response rates and survival compared with standard chemotherapy. Disease control has been proven in the metastatic and, to a limited extent, the adjuvant setting. However, tumor eradication is rare, and duration of treatment response is limited by the development of drug resistance. Conclusions: Kinase inhibitors induce response in diverse types of solid tumors. Although the agents are often effective in defined molecular subsets, cure is rare and resistance is common. This broad review provides rationale for further investigation of multimodality therapy combining kinase inhibitors with additional systemic and local therapies, including surgery.
O ver the past 15 years, the application of kinase inhibitors has revolutionized the therapy of cancer. The ability to attack specific molecular defects in solid tumors has resulted in personalized and rational tumor therapy that goes beyond the less precise approach of using cytotoxic chemotherapy to target DNA and the cell cycle. Here, we define the basic principles of kinase inhibition using small-molecule inhibitors, which share the suffix ''-ib.'' Consideration is given to the mechanism of action, patient selection, radiologic assessment of tumor response, efficacy in the metastatic versus adjuvant setting, acquired resistance to therapy, and multimodality therapy. Examples are provided to illustrate the major concepts. Comprehensive reviews of kinase inhibitors are available elsewhere. [1] [2] [3] 
MECHANISM OF ACTION
Advances in tumor genomic analysis and drug development have dramatically impacted our management of solid tumors as diverse as gastrointestinal stromal tumor (GIST), melanoma, non-small cell lung cancer (NSCLC), medullary thyroid cancer, renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), breast cancer, and pancreatic neuroendocrine tumor (PNET). Such tumors are associated with abnormal activation of protein kinases. Kinases are a class of tightly regulated cellular enzymes that catalyze the transfer of phosphate residues from ATP molecules to specific protein substrates, thereby turning on and off key signaling pathways involved in cell growth, survival, and, when dysregulated, malignancy. To date, more than 20 small-molecule inhibitors have been approved by the US Food and Drug Administration (FDA) for the treatment of advanced solid tumors harboring activating mutations, amplifications, or overexpression of oncogenes encoding ''druggable'' kinases involved in neoplastic cell signaling (Table 1) . 2, 3 These novel agents are low molecular weight, orally bioavailable drugs that traverse the cell membrane, bind selectively to target kinases, and interfere with ATP binding and substrate phosphorylation (Fig. 1) . 2 There are about 500 protein kinases in humans. 40 Kinase targets within the cancer cell can be divided into 2 broad biologic categories: receptor tyrosine kinases (RTKs), which are located on the cell surface and normally transduce extracellular ligand or growth factor signals into the cell; and intracellular serine/threonine or dual specificity tyrosine/threonine kinases, which serve as downstream mediators of growth factor receptors. RTKs include epidermal growth factor receptor (EGFR), anaplastic lymphoma receptor tyrosine kinase (ALK), stem cell factor receptor (KIT), platelet-derived growth factor receptor (PDGFR), rearranged during transfection (RET), human epidermal growth factor receptor 2 (HER2), and hepatocyte growth factor receptor (MET). Meanwhile, the second category includes BRAF, MEK, and mammalian target of rapamycin (mTOR). Most kinase targets converge on 1 or more of the following downstream signaling pathways: PI3K/AKT/mTOR, JAK/STAT, PLC/PKC, and RAS/RAF/MEK/ERK [ERK is a member of the mitogen-activated protein kinase (MAPK) family] (Fig. 1) . 1, 41 The end result is coordinated phosphorylation and nuclear translocation of transcription factor proteins, which together regulate gene expression and the ultimate balance of proliferative and death signals within the cell. Despite the complexity of these intracellular pathways, kinase inhibitors have achieved impressive tumor responses, most notably in patients whose tumors are presumed to be oncogeneaddicted and thus highly dependent on a single driving kinase. 42 
PATIENT SELECTION: NEW TUMOR SUBSETS BASED ON MOLECULAR CLASSIFICATION
As the list of clinically available kinase inhibitors grows, it is clear that molecular classification is necessary to optimize their application to selected patients. In the current genomic era, tumors are increasingly being classified not only by traditional anatomic and histologic categories, but also by molecular subtypes, which have varying sensitivity to targeted agents. For example, NSCLC adenocarcinoma can now be subdivided into at least 10 different genotypes. The most common genetic subtype of NSCLC is a KRAS mutation. 43 KRAS encodes a GTPase involved in signal transduction, and there is intense investigation to develop effective inhibitors to treat KRASmutated NSCLC, colorectal cancer, pancreas cancer, and other tumors. Approximately 10% to 15% of NSCLC instead harbor an activating mutation in the EGFR oncogene 44, 45 (Fig. 2) . Initial studies demonstrated low objective response rates to targeted inhibitors in the general NSCLC population, but subsequent phase 3 clinical trials in selected NSCLC subgroups showed improved survival. A large randomized controlled phase 3 trial was enriched for patients with EGFR mutations and compared the EGFR inhibitor gefitinib against carboplatin-paclitaxel chemotherapy. 46 Among patients treated with gefitinib, those with EGFR mutations had a higher objective response rate than those without mutations (71% vs 1%). Mutation-positive patients had better progression-free survival (PFS) on gefitinib compared with standard chemotherapy [hazard ratio for progression (HR) 0.48, 95% confidence interval (CI) 0.36-0.64]. Notably, those patients without EGFR mutations had worse outcomes when treated with gefitinib rather than chemotherapy (HR 2.85, 95% CI 2.05 to 3.98). 46 In another phase 3 trial of patients with NSCLC containing an EGFR mutation, the EGFR inhibitor erlotinib achieved similar improvement in objective response rate and PFS compared with standard cytotoxic chemotherapy (9.7 vs 5.2 mos). 4 Interestingly, patients with NSCLC and an EGFR mutation tend to be female, Asian, and nonsmokers. 45 Meanwhile, another 1% to 7% of NSCLC contain a chromosomal rearrangement involving the ALK oncogene. 44, 47 In these patients, a phase 3 trial of the ALK inhibitor crizotinib demonstrated a 65% objective response rate and improved PFS (7.7 vs 3 mos) compared with standard chemotherapy. 48 Molecular classification has similarly impacted the management of other cancers, such as melanoma and GIST. Tumor genotyping now allows for the selection of patients with BRAF-mutated melanoma who will benefit from BRAF inhibitors, such as vemurafenib. 5, 49 Furthermore, the presence and specific type of KIT mutation in GIST correlates with imatinib response in metastatic disease. 50 In a phase 3 trial of imatinib in patients with advanced GIST, patients with KITexon 11 mutations had significantly improved overall survival (OS), objective response rate, and time to tumor progression, compared with patients with KIT exon 9 mutations or wild-type tumors, regardless of imatinib dose. 50 Overall, these results underscore the importance of utilizing molecular classification to refine patient and tumor selection for targeted therapy.
For the majority of solid tumors other than NSCLC, melanoma, and GIST, genomic heterogeneity and rare frequencies of actionable mutations make it difficult to stratify patients by tumor genotype and test new targeted agents. To overcome such obstacles, ''basket'' or ''bucket'' clinical trials, such as the National Cancer Institute's multicenter Molecular Analysis for Therapy Choice (NCI-MATCH, NCT02465060), seek to test molecular therapies in patients based solely on tumor genomic alterations rather than histology or 
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MET, 4% FIGURE 2. Genomic analysis identifies numerous molecular subsets of lung adenocarcinoma, a histologic subset of nonsmall cell lung cancer (NSCLC). Based on 230 cases of lung adenocarcinoma analyzed by the Cancer Genome Atlas Research Network, 44 almost two-thirds of the tumors had activating mutations, amplifications, or chromosomal rearrangements of kinase-encoding genes involved in the receptor tyrosine kinase/RAS/RAF/MEK/ERK, or MAP kinase, cell signaling pathway (red/orange). Another 14% of tumors were discovered to have novel genetic changes (ie, ERBB2 or MET amplification) or loss-of-function mutations of the NF1 tumor suppressor gene, which have not been previously characterized in NSCLC patients (blue). Finally, about one quarter of tumors had no identifiable, targetable genetic changes (gray).
anatomic site. 51 Such trials have the potential to identify relevant therapeutic targets across diverse tumor types. New ''umbrella'' trials, such as the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST), are designed to test various targeted agents in patients based on genomic subtype within a given tumor type (eg, NSCLC harboring an EGFR mutation or ALK gene rearrangement). 52 Overall, such trials may change the paradigm of cancer classification and hasten drug development.
RADIOLOGIC ASSESSMENT OF TUMOR RESPONSE: BEYOND RECIST
Cancer therapies have historically been assessed by the reduction in tumor size as determined by radiologic imaging. Initially, the World Health Organization (WHO) criteria were used based on bidimensional measurements of target lesions. 53 Currently, the Response Evaluation Criteria In Solid Tumors (RECIST, 54 RECIST 1.1 55 ) are employed, which use the sum of the single longest diameter of up to 5 target lesions to define partial response (PR, >30% decrease in the sum of diameters), progressive disease (PD, >20% increase in the sum of diameters, or the appearance of new lesions), and stable disease (SD, neither PR nor PD). Although radiologic tumor regression correlates with clinical response to cytotoxic chemotherapy, RECIST criteria may underestimate the efficacy of kinase inhibitors. Many targeted therapies actually fail to induce tumor shrinkage, but nevertheless cause tumor destruction or slow disease progression, indicating the need for better radiologic correlates of drug efficacy. For example, sorafenib is a multikinase inhibitor that inhibits RAF and the downstream ERK/MAPK signaling pathway that is implicated in HCC. In a phase 2 trial of sorafenib in 137 patients with inoperable HCC, objective response rate by modified WHO criteria was low, with only 8% of patients achieving minor or partial response (>25% decrease in the sum of bidimensional measurements of target lesions). 56 Nevertheless, some tumors that increased in size had increased central necrosis on intravenous contrast-enhanced computed tomography (CT), suggesting better drug efficacy than estimated by RECIST (Fig. 3) . 56 In a phase 3 randomized, placebo-controlled trial of sorafenib in patients with advanced HCC, the objective response rate was similarly low by RECIST [no complete response (CR) and 2% PR], but 71% of sorafenib-treated patients demonstrated SD, and sorafenib delayed the time to tumor progression and elicited a modest improvement in OS (10.7 vs 7.9 mos), suggesting that RECIST underestimated drug efficacy. 6 These results may simply reflect tumoristatic rather than tumoricidal effects of some kinase inhibitors like sorafenib. However, it is also possible that alternative radiologic criteria are required to measure drug response and estimate survival benefit. The modified RECIST assessment for HCC (mRECIST), proposed by the American Association for the Study of Liver Diseases, incorporates treatment-induced tumor necrosis into response definitions, including measurements of only the viable, arterially-enhancing regions of target lesions on contrast-enhanced axial imaging. 57 Preliminary studies suggest improved correlation of mRECIST over purely size-based imaging criteria with clinical outcomes in HCC patients on targeted therapy. 58 Decreased tumor attenuation on contrast-enhanced CT has similarly been investigated as a marker of drug effect in other cancers such as GIST and RCC. For example, the Choi criteria for GIST incorporate both tumor size by RECIST and tumor density by Hounsfield units (HU). After imatinib therapy in GIST, Choi criteria outperform RECIST as they better correlate with tumor response, metabolic activity on 18 fluoro-deoxyglucose positron emission tomography (FDG-PET), and PFS. 59 The Size and Attenuation in CT (SACT) criteria, which combine unidimensional tumor measurements and volumetric mean tumor attenuation by HU, have similarly been shown to predict RCC response to sorafenib or sunitinib better than RECIST, mRECIST, or Choi criteria. 60 Newer imaging technologies, such as dynamic contrast-enhanced (DCE)-CT, MRI, and ultrasound, theoretically offer the benefit of assessing tumor vascularity and perfusion, but remain to be validated in the clinical setting. 61 Ultimately, different combinations of tumor size, viability, and perfusion may be required to accurately assess different tumor types in their response to kinase inhibitors. Optimal assessment of drug efficacy will be critical to patient selection in the clinic, and also the evaluation and timely approval of new inhibitors in clinical trials.
EFFICACY IN ADVANCED DISEASE
The efficacy of kinase inhibitors has now been demonstrated in multiple cancers (Table 1) .
5,7 -9,49,62,63 Perhaps, the most dramatic results have been seen in GIST, a gastrointestinal sarcoma driven primarily by the KIT oncogene and less frequently by a PDGFR alpha mutation. Historically, patients with unresectable metastatic GIST had a dismal prognosis, with a median survival less than a year, 64 since conventional cytotoxic chemotherapy was ineffective. 65 A phase 3 trial compared 2 doses of the KIT and PDGFR inhibitor imatinib in patients with unresectable or metastatic GIST. Patients in both treatment arms had about a 40% partial response rate and median PFS was 18 to 20 months. 9 The results were similar in another phase 3 trial and markedly better than historical outcomes with cytotoxic chemotherapy (Fig. 4A) . 63 We now know that the median survival in metastatic GIST is 5 years, 66 which again demonstrates the inadequacy of RECIST criteria in determining tumor response. In fact, some GISTs that respond to tyrosine kinase FIGURE 3. Targeted therapy causes tumor necrosis in the absence of tumor shrinkage. Contrast-enhanced computed tomography scan of a patient with HCC before (A) and after (B, C) treatment with sorafenib, showing an increase in tumor volume and central necrosis in response to treatment. This demonstrates the limitation of relying only on RECIST criteria to evaluate tumor response to targeted therapy. 56 inhibitors may transiently enlarge. Furthermore, small tumors may only become visible on cross-sectional imaging after therapy, when their tumor density changes as discussed above.
While imatinib is clearly effective in advanced GIST, it is important to realize that it is rarely curative, and nearly all patients will eventually develop tumor progression, even after 10 years of therapy. In a phase 3 trial, patients with advanced GIST who had received 1 year of imatinib therapy and had responsive disease were randomly assigned to continue imatinib or suspend treatment. 67 Of 26 patients assigned to continue imatinib treatment, only 8 patients (31%) experienced disease progression compared with 26 of 32 patients (81%) who stopped imatinib therapy. The median time to progression after cessation of imatinib therapy was 6 months, but most (92%) responded after restarting imatinib. Thus, tumors can respond after premature stoppage of kinase inhibition, but also can acquire resistance (vide infra) during chronic therapy. These phenomena have also been observed in NSCLC and other tumors.
EFFICACY AS ADJUVANT THERAPY
Given the efficacy of imatinib in patients with advanced GIST, 9, 63, 66, 68 and the historical disease-specific survival of 54% in patients with primary GIST who underwent complete resection, 64 imatinib was tested in the adjuvant setting. 10 In the initial phase 3 trial, 1 year of imatinib was compared with placebo after the resection of localized, primary GIST. One-year recurrence-free survival (RFS) was improved in the imatinib arm compared with the placebo arm (98% vs 83%) (Fig. 4B) . 69 However, there was no difference in OS, even after long-term follow-up, 70 likely due to the rescue effect of imatinib in patients on the placebo arm who developed recurrence that was detected early with serial radiologic imaging. Multivariate analysis of variables associated with decreased RFS identified tumor size, mitotic index, and primary tumor location. Notably, mutation subtype was not found to be an independent prognostic factor on multivariate analysis, which is likely due to the small number of patients per group. In subgroup analysis, patients with KIT exon 11 deletions had improved RFS with adjuvant imatinib therapy versus placebo, whereas patients with wild-type tumors did not. 70 It is known that the PDGFR alpha D842V mutation found in about 5% of primary GISTs is not sensitive to imatinib. Consistent with the rarity of cure in advanced GIST, 1 year of adjuvant imatinib therapy did not alter long-term RFS. 70 Another trial compared 1 and 3 years of adjuvant imatinib in patients at high risk of recurrence. 11 In patients who received 3 years of imatinib, the 5-year RFS was increased (66% vs 48%), as was OS (92% vs 82%). Importantly, though, there was no difference in disease-specific survival.
Thus, adjuvant imatinib may delay tumor recurrence by suppressing tumor growth. This finding raises important questions about the optimal use and timing of adjuvant molecular therapy. If the goal is to increase RFS, then chronic (>3 yrs) therapy should be considered. Currently, a phase 2 trial of 5 years of adjuvant imatinib is ongoing. 71 Alternatively, patients could be followed carefully with serial radiologic imaging and started on therapy only if tumor recurrence occurs. Since over 70% of patients are cured with surgery alone, better indicators of the likelihood of recurrence, such as a nomogram, 72 can assist with decision-making.
ACQUIRED RESISTANCE TO TARGETED THERAPY
Despite the efficacy of targeted therapy, acquired resistance occurs frequently. Genetic changes that alter the structure of the target enzyme and compensatory signaling within the cancer cell represent the major mechanisms of acquired resistance to kinase inhibitors, whereas pharmacokinetic changes in drug delivery and metabolism are less well characterized (Fig. 5) .
We highlight several mechanisms of acquired resistance using EGFR-mutant NSCLC as an example. Exon 19 deletions and the point mutation L858R account for approximately 90% of primary EGFR mutations. 73 Kinase inhibitors targeting EGFR are effective against this subset of tumors, but the median time to erlotinib or gefitinib resistance is only 12 months. 46, 74 The predominant resistance mechanism (50%-60%) is a secondary mutation in EGFR, emphasizing its importance in tumor maintenance. About 90% of secondary mutations occur in exon 20 and encode the substitution of methionine for threonine at position 790 (T790M), the so-called gatekeeper residue at the opening of the ATP-binding pocket that is essential for kinase activity and which is conserved across many RTKs. 75 Structural modeling of the T790M secondary mutation demonstrates an alteration of the ATP-binding pocket of EGFR likely resulting in steric hindrance to erlotinib and gefitinib binding, due to the larger size of methionine as compared with threonine. 76 ATP binding remains intact, leading to persistent oncogenic EGFR signaling.
Approximately 20% of patients with acquired resistance to EGFR kinase inhibitors instead demonstrate activation of accessory intracellular signaling pathways. Multiple mechanisms have been FIGURE 4. Efficacy of imatinib in (A) metastatic and (B) resected localized, primary GIST. A, Overall survival in patients with metastatic GIST treated with imatinib once or twice daily compared with historical controls in the EORTC database treated with doxorubicin. 63 B, Recurrence-free survival in patients with high-risk, resected primary GIST randomized to 1 year of imatinib or placebo. The 1-year estimated recurrencefree survival was 98% (95% CI 96-100) in the imatinib group versus 83% (95% CI 78-88) in the placebo group. 69 
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reported, emphasizing the remarkable plasticity of cancer. Amplification of MET, which encodes a RTK that activates the PI3K and MAPK pathways, confers resistance to EGFR kinase inhibitors. 77, 78 An EGFR to MET ''kinase-switch'' has been shown with MET activation of the PI3K pathway through ERBB3 signaling. 78 Overexpression of hepatocyte growth factor, the natural ligand of MET, has also been found to confer EGFR kinase inhibitor resistance through MET-induced restoration of PI3K pathway signaling. 79 Similarly, overexpression of AXL, which encodes the AXL RTK, and its ligand GAS6, can cause EGFR inhibitor resistance by activating the PI3K and MAPK pathways. 80 Mutations downstream of EGFR, within the PI3K/ AKT and MAPK signaling pathways, also confer decreased sensitivity to EGFR kinase inhibitors. These include activating mutations of PIK3CA, KRAS, and BRAF V600E, and loss-of-function mutations of the tumor suppressor gene PTEN. 80 Another mechanism of acquired resistance to EGFR kinase inhibitors in NSCLC is histologic transformation. In a study analyzing pre-and post-treatment biopsies of 37 patients who developed resistance to gefitinib or erlotinib, 5 patients experienced a transformation of their tumor to a small cell lung cancer histology and 2 other patients demonstrated epithelial-to-mesenchymal transition. 81 All tumors maintained their original EGFR mutation. 81 The molecular events responsible for these histologic changes remain to be elucidated.
Similar mechanisms of acquired resistance to targeted agents have been revealed in other tumors. Secondary KIT mutations account for imatinib resistance in over half of GIST patients. 82 MET activation has also been shown in GIST. 83 In patients with advanced BRAF-mutated melanoma, BRAF inhibitors are initially effective, but disease progression occurs at approximately 6 months. 5, 8, 49, 84 Reactivation of the MAPK signaling pathway occurs in a variety of ways, including expression of the MAPK agonist COT, up-regulation of RAS, kinase switching, and alternative splicing of BRAF leading to enhanced BRAF dimerization. 85, 86 
MULTIMODALITY THERAPY
Because acquired resistance to single-agent kinase inhibitor therapy is a frequent occurrence and limits therapeutic durability, attention has turned to combination approaches. Here, we will highlight combination therapy in BRAF-mutated melanoma, including surgery for patients with previously unresectable or metastatic disease. Combination of kinase inhibitors with other types of therapy, such as cytotoxic chemotherapy or radiation, is also under investigation, but beyond the scope of this review.
Approximately 50% of malignant melanomas harbor a BRAF mutation, most commonly a substitution of valine to glutamic acid at position 600 (V600E). 87 Multiple phase 3 trials have demonstrated increased response rates, PFS, and OS in patients with advanced BRAF V600-mutated melanoma treated with the BRAF inhibitors vemurafenib or dabrafenib compared with dacarbazine. 5, 8, 31, 49, 84, [88] [89] [90] Despite initial efficacy, disease progression occurs at 6 months. 5, 8, 49, 84 Under normal circumstances, BRAF phosphorylates the MAPKs MEK1 and MEK2, which activate downstream signaling. One mechanism of resistance to BRAF inhibition, mentioned above, is reactivation of the MAPK pathway via BRAF-independent, MEKdependent signaling. 85 A phase 3 trial comparing the MEK inhibitor trametinib to conventional cytotoxic chemotherapy in patients with advanced BRAF V600-mutated melanoma found a >50% relative risk reduction of disease progression and death with trametinib. 12 Similar to patients treated with BRAF inhibitors, however, median time to disease progression was 5 months. 5, 8, 12, 49, 84 Given the transient efficacy of single-agent BRAF and MEK inhibition, multiple studies were conducted combining the approaches. A phase 3 trial showed that dabrafenib plus trametinib had a higher overall response rate (67% vs 51%) and 25% relative risk reduction in disease progression compared with dabrafenib monotherapy. 91 Another phase 3 trial indicated that dabrafenib plus trametinib had greater PFS (11.4 vs 7.3 mos) and OS (not reached vs 17.2 mos) than vemurafenib monotherapy (Fig. 6) . 13 A phase 3 trial comparing combined vemurafenib plus cobimetinib (another MEK inhibitor) resulted in a higher objective response rate (68% vs 45%) and longer median PFS (9.9 vs 6.2 mos) than vemurafenib monotherapy.
14 Doselimiting toxic events in the monotherapy and combination therapy groups in the above studies were similar. 13, 91, 92 Notably, patients treated with BRAF inhibitor monotherapy experienced higher rates of cutaneous squamous cell carcinoma, due to activation of the MAPK pathway, compared with patients treated with combined BRAF and MEK inhibition. 49, 92 Overall, these trials demonstrate modest improvement of combination BRAF and MEK inhibitor therapy over monotherapy in advanced BRAF-mutated melanoma.
Although kinase inhibitors are effective, their limited duration of response has prompted investigation of alternative approaches, such as immune therapy. Melanomas are notable for their high mutational burden and immunogenicity. In a subset of patients with advanced melanoma, the T-cell-activating checkpoint inhibitors anti-CTLA-4 (ipilimumab) and anti-PD-1 (nivolumab, pembrolizumab) have demonstrated long-lasting responses. [93] [94] [95] [96] The goal of combining these immune therapies with molecular agents is to achieve durable responses in a larger proportion of patients. Preclinical and translational studies support this approach. In mouse models of BRAF-mutated melanoma, BRAF and MEK inhibition were more effective at controlling tumor growth when combined with checkpoint inhibition. 97, 98 In melanoma patients, BRAF inhibition led to increased intratumoral expression of the T-cell exhaustion markers TIM-3 and PD-1, and also the immunosuppresive ligand PD-L1, suggesting an immune-mediated mechanism of BRAF inhibitor resistance. 99 Based on these data, clinical trials are now investigating the combination of kinase and immune checkpoint inhibitors. A phase 1 trial was initiated to test vemurafenib plus ipilimumab in patients with untreated BRAF V600-mutated advanced melanoma, but the study was closed early due to grade 3 hepatotoxicity. 100 Preliminary data from phase 1 trials testing alternative BRAF and MEK inhibitors (dabrafenib, trametinib) with ipilimumab or anti-PD-L1 (MEDI4736) demonstrate more favorable toxicity profiles. 101, 102 Studies are ongoing to evaluate efficacy. 103, 104 Combining molecular therapy with surgery remains poorly defined. Historically, resection of advanced melanoma has been reserved for patients with local recurrence and in-transit, satellite, and oligometastatic disease, with improvement in OS. 105, 106 Retrospective data suggest that patients with metastatic melanoma who respond to BRAF inhibition, but have an isolated focus of residual or progressive disease, may benefit from metastasectomy. 107 Similarly, patients with metastatic GIST may benefit from metastasectomy after response or disease stabilization with imatinib. 107 However, randomized clinical trials are lacking and have been difficult to conduct. Nevertheless, surgery may serve as an ''adjuvant therapy'' to kinase inhibition in highly selected patients. Additionally, patients with advanced melanoma treated with neoadjuvant BRAF inhibition have been reported, 108 and the role of neoadjuvant combination targeted therapy in patients with resectable, high-risk metastatic melanoma is under formal investigation. 109 
CONCLUSIONS
Kinase inhibitors have revolutionized cancer therapy and are effective in selected patients with advanced solid tumors. Despite initial efficacy, however, kinase inhibitors are not curative. Development of resistance is common, emphasizing the urgency to identify new therapeutic targets and more effective treatment strategies. Molecular subclassification of tumors is needed to better select patients and predict treatment response. Combination therapy is anticipated to improve outcomes in many tumor types, and surgery remains a relevant part of the shifting treatment paradigm. FIGURE 6. Combined BRAF and MEK inhibition is more effective than BRAF inhibition alone. Kaplan-Meier estimates of overall survival in the intention-to-treat population of patients with advanced melanoma treated with combination dabrafenib and trametinib compared with vemurafenib monotherapy.
